Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
Izanne Roos(The Royal Melbourne Hospital), Vincent Van Pesch(Cliniques Universitaires Saint-Luc), Melinda Magyari(University of Copenhagen), Charles B. Malpas(The Royal Melbourne Hospital), Murat Terzi(Ondokuz Mayıs University), Cees Zwanikken, Sifat Sharmin(The Royal Melbourne Hospital), Jeannette Lechner‐Scott(John Hunter Hospital), Sivagini Prakash(Regionshospitalet Viborg), Leontien Den Braber‐Moerland, Guy Laureys(Ghent University Hospital), Nevin John(Monash Health), Matthias Kant(Sygehus Sønderjylland), Tomáš Kalinčík(The Royal Melbourne Hospital), Katherine Buzzard(The Royal Melbourne Hospital), Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Anneke van der Walt(The Alfred Hospital), Jens Kühle(University of Basel), Raed Alroughani(Amiri Hospital), Ismael Barzinji, Cavit Boz(Farabi Hastanesi), Pamela McCombe(The University of Queensland), Peter Vestergaard Rasmussen(Aarhus University Hospital), François Grand’Maison, Suzanne Hodgkinson(UNSW Sydney), Justin Garber, Mark Slee(Flinders University), Jennifer Massey, Pierre Grammond(Centre intégré de santé et de services sociaux de Chaudière-Appalaches), Tobias Sejbæk(University of Southern Denmark), Bruce Taylor(Royal Hobart Hospital), Aysun Soysal(Bakırköy Psychiatric Hospital), Arkadiusz Wêglewski(Rigshospitalet), Helle Hvilsted Nielsen(University of Southern Denmark), Liesbeth Van Hijfte(Ghent University Hospital), Michael Barnett(The University of Sydney), Morten Stilund, Serkan Özakbaş(İzmir University of Economics), Ana Voldsgaard Jensen(Copenhagen University Hospital), Orla Gray(South Eastern Health and Social Care Trust), Kristina Bacher Svendsen(Aarhus University Hospital), Olga Skibina(Box Hill Hospital), E Roullet, Nadia Mubder Issa(Zealand University Hospital), José Antonio Cabrera-Gómez(Multiple Sclerosis Society), Gavin McDonnell(University of Ulster), Richard Macdonell, Stella Hughes(University of Ulster), Finn Sellebjerg(Danish Multiple Sclerosis Center)
Cited by 62
Related Papers
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
|Science|2022|2k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
|Neurology|2014|1.3k
Multiple Sclerosis Severity Score
|Neurology|2005|957